罗格列酮对非糖尿病代谢综合征患者血清脂联素水平和胰岛素抵抗的影响

目的：观察罗格列酮（ROS）对非糖尿病代谢综合征（MS）患者血清脂联素水平和胰岛素抵抗性的影响。方法：选择92例非糖尿病MS患者随机分为两组，A组40例，给予常规治疗；B组52例，在常规治疗上的基础上，加用罗格列酮（ROS）口服。用药前及用药后8周，应用酶联免疫吸附法测定血清脂联素水平、计算胰岛素抵抗指数、胰岛素敏感指数。结果：A组治疗前后脂联素水平（1．49±0．59mg／L vs 1．21±0．66mg／L，P〉0．05）及胰岛素抵抗指数（1．44±0．51 vs 1．32±0．57，P〉0．05）、胰岛素敏感指数（-4．56±0．51vs -4．44±0．57，P〉0．05）比较无显著性差异；B组治疗前后比较，脂联素水平升高（0．89±0．73mg／L vs 2．52±1．37mg／L，P〈0．01）、胰岛素抵抗指数降低（1．50±0．45 vs 0．99±0．35，P〈0．01）、胰岛素敏感指数升高（-4．61±0．45 vs -4．10±0．46，P〈0．01）均有统计学意义。结论：非糖尿病MS患者经口服ROS后脂联素水平明显升高、胰岛素抵抗指数降低、胰岛素敏感指数升高。

Effect of Rosiglitazone on Serum Adiponectin Levels and Insulin Resistance in Patients with Non -Diabetic Metabolic Syndrome

Objective To investigate the effect of rosiglitazone （ROS） on serum adiponectin levels and insulin resistance in patients with non - diabetic metabolic syndrome （MS）. Methods 92 non0diabetic MS patients were divided randomly into group （ n = 40） A： conventional tretment only and group B （n =52） ROS 4mg p. o qd plus conventional treatment. Serum adiponectin levels （ with ELISA） and homeostasis insulin resistance index （ Homa - IR）, insulin sensitivity index （ISI） were examined both before treatment and after 8 weeks. Results The serum adiponectin level （ 1.49 ± 0.59mg/L vs 1.21 ± 0.66rag/L, P 〉 0.05）, ISI （ - 4.56±0.51 vs - 4.44 ± 0.57, P 〉 0.05 ） and Homa - IR （ 1.44 ± 0.51 vs 1.32 ± 0.57, P 〉 0.05 ） were not significantly changed in group A patients after 8 weeks＇ treatment. There was a significant increase in serum adiponeetin levels （0.89 ± 0.73mg/L vs 2.52 ± 1.37mg/ L, P〈0.01） and ISI （ -4.61±0.45 vs -4.10±0.36, P〈0.01） with a significant decrease in Homa -IR （1.50 ± 0.45 vs 0.99 ± 0.35, P 〈 0.01 ） in group B patients after ROS treatment. Conclusion There was a sigrtifieant increase in serum adiponeetin level and ISI, with a significant decrease in Homa - IR in non - diabetic MS cases after 8 weeks＇ treatment with ROS.